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Primary aldosteronism (PA) is characterized by adre-nocortical oversecretion of aldosterone, which causes 
increased cardiovascular and metabolic morbidity.1–4 In most 
cases, PA is either caused by bilateral adrenal hyperplasia 
or unilateral aldosterone-producing adenoma (APA).5 Swift 
and thorough diagnostic evaluation is of high importance 
for further therapeutic decision-making: although APA may 
be cured by surgery, therapy of bilateral adrenal hyperplasia 
consists of life-long treatment with mineralocorticoid receptor 
antagonists.6 Conventional imaging reveals adrenal lesions 
with an age-dependent increase and an overall prevalence of 
2% to 10%, mainly representing nonfunctioning adenomas 
(NFAs).7 Thus, NFA coincident with biochemical PA may be 
falsely interpreted as APA instead of bilateral adrenal hyper-
plasia, potentially leading to avoidable surgical interventions. 
Accordingly, conventional imaging methods still do not allow 
for an unequivocal differential diagnosis in patients with 
PA.8–10 Adrenal vein sampling (AVS) has, therefore, remained 
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the standard procedure in these cases, despite its expense and 
availability only in major centers.6,11,12 Moreover, AVS is an 
invasive technique that is not well standardized between cen-
ters and heavily depends on the expertise of the interventional 
radiologist.13,14 AVS furthermore requires the use of contrast 
agents in a patient population that often experiences impaired 
renal function.15 To date, proposed clinical prediction scores 
cannot replace AVS.16–20 An interesting novel approach con-
sists of the measurement of a selected steroid profile by mass 
spectrometry.21,22 Nevertheless, additional diagnostic steps 
will be needed to localize potential APA.
In this context, functional imaging techniques are of 
great interest. As a potential target, CYP11B2 (aldosterone 
synthase) has been investigated, and a selective CYP11B2 
inhibitor has recently shown promising results as radiotracer 
for positron emission tomographic (PET) imaging in first pre-
clinical studies.23
Chemokines belong to a class of cytokines that exert 
important physiological effects on organ development, cell 
migration, and tissue ultrastructure by binding to their specific 
receptors. In recent years, the role of chemokine receptors in 
malignant behavior of human cancers has emerged as a par-
ticular research focus.24–26 CXCR4 (CXC chemokine recep-
tor type 4) binds its ligand—the CXC chemokine CXCL12 
(stromal cell-derived factor-1). Recently, a second CXCL12 
receptor—CXCR7 (the nonclassical/atypical CXC chemo-
kine receptor 7)—has been identified.27,28 To date, limited data 
are available on the expression of chemokine receptors in the 
adrenal cortex, and the presence and functional relevance of 
chemokine receptors in adrenocortical tumors have not yet 
been evaluated in detail.
We, therefore, investigated the expression of chemokine 
receptors in the normal adrenal (NA) and in benign adreno-
cortical tumors. Because we found high expression of CXCR4 
particularly in the zona glomerulosa of the adrenal cortex, we 
were further interested in the potential of the recently devel-
oped CXCR4 ligand 68Ga-pentixafor29–31 (68GaCPCR4.2) for 
molecular imaging of aldosterone-producing tissue.
Materials and Methods
Availablility of Data, Analytical Methods, and Study 
Materials
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Immunohistochemical Analysis and Quantitative 
Polymerase Chain Reaction
Immunohistochemistry was performed in formalin-fixed and paraf-
fin-embedded specimens of 2 NAs and 220 patients with known adre-
nocortical adenomas (117 APAs, 49 NFAs, and 54 cortisol-producing 
adenomas [CPAs]). The adjacent adrenal cortex was evaluated in 191 
of 220 tumor samples. Tissue specimens and corresponding clinical 
data were derived from 5 tertiary referral centers from the University 
Hospitals of Berlin, Essen, Munich, Turin, and Wuerzburg. Patients 
with unilateral APA had been diagnosed according to the 2008 
Endocrine Society Practice Guidelines.32 Collection of patient data 
and samples was approved by the ethical committees of the respective 
institutions (Wuerzburg 88/11, Essen 01-187-1787-Z, Charité Berlin 
EA1/169/08,33 Munich 379/10, Turin CEI/349). All patients had pro-
vided written informed consent.
Chemokine receptor mRNA expression levels were investigated by 
quantitative real-time polymerase chain reaction. RNA was isolated 
from fresh frozen tissue of 12 APAs, 11 CPAs, and 3 NFAs using the 
RNeasy Lipid Tissue Minikit (Qiagen, Alameda, CA) and reversely 
transcribed using the QuantiTect Reverse Transcription Kit (Qiagen).
For details, please see the online-only Data Supplement.
Imaging With 68Ga-Pentixafor
Synthesis of 68Ga-pentixafor was performed in Munich and Wuerzburg 
in a fully automated, good manufacturing practice–compliant pro-
cedure using a GRP module (Scintomics GmbH, Fürstenfeldbruck, 
Germany) equipped with disposable single-use cassette kits (ABX, 
Radeberg, Germany), using the method and standardized labeling 
sequence described previously.30,31,34 Before injection, the quality of 
68Ga-pentixafor was assessed according to the standards described 
in the European Pharmacopoeia for 68Ga-Edotreotide (European 
Pharmacopoeia, monograph 01/2013:2482, available at www.edqm.
eu). The radiochemical purity of the ready-to-inject formulation as 
confirmed by radio–high-performance liquid chromatography and 
radio–thin-layer chromatography was >99%.
In autoradiographic experiments, binding of 68Ga-pentixafor to 
cryosections from 4 APAs, 4 NFAs, 2 adrenocortical carcinomas, 
and 3 NAs was analyzed. One slide was treated with 2 MBq 68Ga-
pentixafor, and another slide was incubated with 2 MBq 68Ga-
pentixafor plus 10 µmol/L of nonradioactive compound to monitor 
specific binding.
To evaluate the suitability of 68Ga-pentixafor for in vivo imaging 
of APA, 9 patients with APA were investigated: 3 at the University 
Hospital Wuerzburg (all by PET/computed tomography [CT]) and 
6 at the Technical University of Munich (1 patient by PET/CT and 
5 patients by PET/magnetic resonance imaging). Reference values 
for 68Ga-pentixafor uptake in NA glands were established by ret-
rospective analysis of 68Ga-pentixafor-PET imaging results from 
patients with multiple myeloma (n=20),29 pleural mesothelioma 
(n=6), and gastrointestinal tumors (n=18) that had been investigated 
for individual assessment of eligibility for endoradiotherapy with 
177Lu-Pentixather. In these patients, no adrenal tumor lesion was 
documented on conventional CT. CT and magnetic resonance imag-
ing scans were scored by a board-certified radiologist, and all PET 
scans were scored by a board-certified nuclear medicine physician. 
For details, please see the online-only Data Supplement.
Statistical Analysis
All statistical tests were performed using either SPSS23 or Graph-
pad PRISM6. P values <0.05 were considered statistically significant. 
Quantitative values were expressed as mean±SEM or median and range 
as appropriate. Comparisons of related metric measurements were per-
formed using Wilcoxon signed-rank test, and the Mann–Whitney U test 
was used to compare quantitative data between 2 independent samples. 
In addition, the χ2 test was performed for comparison of APA, CPA, 
and NFA grouped for high or low expression of CXCR4. Correlation 
between CYP11B2 and CXCR4 staining scores was examined by cal-
culation of Pearson correlation coefficient. Receiver operating char-
acteristic analysis was performed for maximum standardized uptake 
values (SUV
max
values) of controls and APA with Graph-pad PRISM6.
Results
Immunohistochemical Analysis of CXCR4, 
CYP11B1, CYP11B2, and CXCL12
In NA, CXCR4 staining was particularly strong in the sub-
capsular region. CYP11B2-positive areas exhibited particu-
larly strong CXCR4 expression (Figure 1A). However, the 
CXCR4-positive area was broader compared with the area of 
CYP11B2-positive cells. CXCL12 showed a complementary 
distribution pattern with low expression in the subcapsular 
area of the adrenal cortex but strong staining in the inner adre-
nocortical zones (Figure 1A). As for NA, a similar staining 
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pattern was found for CXCR4 and CXCL12 in APA (n=5), 
CPA (n=5), and NFA (n=5; Figure 1B and 1C). CXCR7 was 
expressed equally in all adrenocortical zones (data not shown).
In adrenocortical adenomas, high CXCR4 membrane 
staining was found in 71% of APAs (Figure 1B; Figure S2 
in the online-only Data Supplement), 26% of CPAs and 4% 
of NFAs. Eight NFAs were completely CXCR4 negative 
(Table 1).
Comparison of membrane staining intensity revealed 
highly significant differences between NFA and APA 
(P<0.001). Likewise, a significant positive correlation was 
observed between CXCR4 membrane staining and CYP11B2 
staining intensity in APA (r=0.42; P<0.01). CYP11B1 was 
coexpressed in 81% of APAs, 100% of CPAs and 98% of 
NFAs (Table 2).
CXCR4 immunostaining was observed in all adjacent 
adrenal cortices independent of the underlying adrenal tumor 
(Table 1).
No differences were observed on clinical parameters or 
mutational status among patients with APA when group-
ing them according to the CXCR4 staining intensity of their 
respective tumor (Table 2).
Quantitative Analysis of Chemokine Receptor 
Expression
Quantitative real-time polymerase chain reaction revealed high 
mRNA levels for CXCR4 and CXCR7 in all adrenocortical 
tumor tissues. However, CXCR4 and CXCR7 expression 
showed considerable variation and did not differ significantly 
between adenoma types at mRNA level. Furthermore, other 
chemokine receptors were found to be expressed at lower 
Figure 1. CXCR4 (CXC chemokine receptor type 4) staining is particularly high in aldosterone-producing tissue, whereas CXCL12 (stromal 
cell-derived factor-1) shows a complementary expression pattern. A, Immunohistochemical staining of CXCR4, CXCL12, CYP11B2 
(aldosterone synthase), and CYP11B1 in the normal adrenal. Magnification ×25. Strong CXCR4 staining was detected in the outer part 
of the normal adrenal cortex covering a broader and more continuous area compared with CYP11B2, which was predominantly found in 
subcapsular aldosterone-producing cell clusters. CXCL12 showed a complementary staining pattern to CXCR4 with missing expression 
in the outer cortical part but strong staining in the inner adrenocortical zones. B, Representative images for aldosterone-producing 
adenoma (APA). Strong CXCR4 staining was observed in the APA, which correlated with CYP11B2 staining, whereas CXCL12 staining 
was observed only in the surrounding adrenocortical tissue (SAT). Magnification ×10. C, Representative images for nonfunctioning 
adenoma (NFA). Immunohistochemical staining for CXCR4 and CYP11B2 was negative; in contrast, strong CXCL12 staining was 
observed in the adenoma (A). Magnification ×10.
Table 1. CXCR4 Protein Expression in Samples From 
Standard Full Slides in 117 APAs, 54 CPAs, and 49 NFAs
CXCR4
n
Low Membrane 
Staining, n (%)
High Membrane 
Staining, n (%)
h score ≤1 >1
APA 117 34 (29%) 83 (71%)
CPA 54 40 (74%) 14 (26%)
NFA 49 47 (96%) 2 (4%)
Adjacent adrenal
  APA 108 66 (61%) 42 (39%)
  CPA 47 31 (66%) 16 (34%)
  NFA 36 26 (72%) 10 (28%)
Semiquantitative h score was calculated by multiplying the staining intensity 
grading score with the proportion score (0.1=1%–9%, 0.5=10%–49%, 1=50% 
or more cells with CXCR4 staining, respectively). Significant differences were 
observed for comparison of APA with NFA and also for comparison of APA with 
CPA, P<0.001, respectively. CPA versus NFA, P=0.002. No significant differences 
between tumor entities were observed for CXCR4 membrane staining intensity 
in adjacent adrenal cortex. APA indicates aldosterone-producing adenoma; CPA, 
cortisol-producing adenoma; CXCR4, CXC chemokine receptor type 4; and NFA, 
nonfunctioning adenoma.
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levels, especially CCR11, CCR7, and CCR3 (C-C chemokine 
receptor types 11, 7 and 3) in NA and CXCR2 (CXC chemo-
kine receptor type 2), CCR2 (C-C chemokine receptor type 2), 
and CCR11 in APA, CPA, and NFA (Figure 2).
Autoradiographic Experiments With 68Ga-
Pentixafor
Autoradiographic visualization of 68Ga-pentixafor revealed 
strong specific binding to APA and adrenocortical carcinoma 
tissues and the outer cortical zones of the NA (Figure 3A). No 
binding was observed to NFA.
68Ga-Pentixafor PET Imaging In Vivo
Further information on patients with PA, results of imaging, AVS, 
and clinical outcome is given in Table 3. 68Ga-pentixafor uptake 
in the area of the adrenal nodule of patients with PA was observed 
with median SUV
max
=8.6 (4.7–18.3), in the contralateral adrenal 
values were significantly lower: SUV
max
=4.0 (2.3–6.5; P<0.001). 
Only 1 patient with a 6-mm tumor showed lower 68Ga-pentixafor 
uptake at the side of surgery. In the control group, SUV
max
 values 
ranged from 1.0 to 5.8 (mean SUV
max
: left adrenal gland, 3.4; 
right adrenal gland, 3.0; Figure 3D). Histopathology confirmed 
the tumors to be adrenocortical adenomas. CXCR4 immunore-
activity was investigated in 4 patients being strongly positive for 
CXCR4 (h score, 2 in 3 cases and h score, 3 in 1 case). All tumors 
also showed positive CYP11B2 staining.
Additionally, ratios were calculated for SUV
max
 values by 
dividing the higher SUV through the lower level of the respec-
tive contralateral side in controls and by dividing the SUV
max
 
value of the side of APA through the contralateral side in 
patients with PA. Ratios from patients with APA significantly 
differed from ratios of controls (APA: mean, 2.8±0.5; control: 
mean, 1.5±0.08; P<0.001). In receiver operating characteristic 
analysis, a cutoff value for SUV
max
 of 4.9 revealed a sensi-
tivity of 88.9% (95% confidence interval, 51.8–99.7) and a 
specificity of 87.2% (95% confidence interval, 78.3–93.4) for 
diagnosing APA. Setting specificity to 100% a cutoff value 
of 7.3 was calculated (sensitivity, 77.8%), whereas a sensitiv-
ity of 100% was reached at a cutoff value of 4.7 (specific-
ity, 83.7%). Area under the curve was 0.964 (95% confidence 
interval, 0.92–1.01; Figure 3E).
Discussion
The key in vitro finding of our investigation is the high expres-
sion of the chemokine receptors CXCR4 and CXCR7 in aldo-
sterone-producing tissue. In contrast, expression of CXCR4 
was negative or only weak in almost all nonfunctioning adre-
nocortical adenomas. Based on this differential expression pat-
tern, we investigated the available PET tracer 68Ga-pentixafor, 
which selectively binds to human CXCR4,29,35 thus represent-
ing a potentially suitable imaging biomarker for noninvasive 
differential diagnosis in PA.
Quantitative real-time polymerase chain reaction revealed 
the expression of several chemokine receptors in both NA 
and adrenocortical adenomas. The most highly expressed 
receptors were CXCR7 and CXCR4: the high expression 
levels found in NAs suggest an important role in adrenal 
physiology. Interestingly, CXCR4 protein expression in the 
adrenal cortex was particularly high in the outer part of the 
adrenal cortex. In contrast, immunohistochemical staining of 
its ligand CXCL12 was highest in the inner adrenocortical 
zones. Because migration of CXCR4-expressing cells along 
a CXCL12 gradient has been demonstrated for different 
cells,26,36 it is possible to speculate that the expression pattern 
of CXCR4 and CXCL12 is involved in the proposed centrip-
etal migration and transdifferentiation of adrenocortical cells. 
In this model, it is hypothesized that undifferentiated pro-
genitor cells in the subcapsular region give rise to differen-
tiated mineralocorticoid-producing zona glomerulosa cells, 
which migrate centripetally and undergo lineage conversion 
into glucocorticoid-producing zona fasciculata and reticularis 
cells.37,38 In this context, the CXCL12 gradient might play a 
major role for the migration direction of adrenocortical cells. 
An alternative hypothesis is that the observed expression pat-
tern is relevant for the ultrastructural organization of the adre-
nal cortex and local cell–cell interaction as has been shown 
for other tissues.39,40 CXCR7 also binds CXCL12. It has been 
shown to exert a scavenger function and modulate CXCL12–
CXCR4 signaling.41 However, the precise physiological role 
of the CXCL12/CXCR4/CXCR7 system in the NA remains 
to be elucidated.
Corresponding to the high expression of CXCR4 in 
the outer adrenal cortex, high expression levels were also 
found in APA, whereas expression in NFA was almost neg-
ligible. CXCR4 expression and CYP11B2 expression levels 
Table 2. Clinical Parameters of Patients With APA Included in 
the Immunohistochemical Analysis
Patient Data
CXCR4 CXCR4
P 
Value
h score ≤1 h score >1
n=34 n=83
Age at diagnosis, y (median; 
range)
49 (26–67) 49 (18–75) 0.9
Sex (M/F), % 44/56 39/61 0.6
SBP, mm Hg 170±22 160±26 0.1
DBP, mm Hg 100±11.5 100±15 0.2
Serum potassium, mmol/L 3.0±0.6 3.0±0.7 0.9
Plasma aldosterone, ng/L n=23 n=48 0.5
520 (208–1950) 500 (57–1148)  
Mutation status of APA, n 25 58 0.1
  WT 15 23  
  KCNJ5 7 28  
  ATPAS 1 5  
  CACNA1D 2 2  
Additional CYP11B1 expression 
detected by IHC (percentage 
of tumors)
73 84 0.2
Group comparison according to CXCR4 membrane staining of the respective 
APA. No statistically significant differences were found between groups. APA 
indicates aldosterone-producing adenoma; ATPAS, ATPase (Na/K-ATPase); 
CACNA1D, calcium voltage-gated channel subunit alpha1 D; CXCR4, CXC 
chemokine receptor type 4; DBP, diastolic blood pressure; F, female; IHC, 
immunohistochemistry; KCNJ5, G protein-activated inward rectifier potassium 
channel 4; M, male; SBP, systolic blood pressure; and WT, wild type.
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correlated significantly, further emphasizing the particu-
larly high expression of CXCR4 in aldosterone-producing 
tissue, which was independent of sex, clinical parameters, 
or mutational status. On the background of these findings, 
68Ga-pentixafor PET imaging might be a useful tool for non-
invasive characterization of adrenal lesions in PA. The results 
from the autoradiographic studies fit well with the findings 
from our immunohistochemical analyses. Strong binding of 
68Ga-pentixafor could be documented for APA and parts of 
the NA cortex in contrast to NFA that did not show relevant 
tracer binding.
11C-metomidate PET imaging has recently been used in 
patients with primary PA and was able to identify aldoste-
rone-producing tissue in these patients with high imaging 
quality. Metomidate binds to both enzymes CYP11B1 and 
CYP11B2 with high avidity.42 Our observation of expression 
of both CYP11B1 and CYP11B2 in most APAs matches with 
the observed high 11C-metomidate uptake in the aldosterone-
producing tissue.43,44 However, 98% of the NFAs in our series 
also exhibited CYP11B1 staining, and both 11C-metomidate 
uptake and 123I-iodometomidate uptake in NFA have been 
demonstrated in clinical studies.45,46 CYP11B1 downregula-
tion may be achieved in normal surrounding adrenocortical 
tissue by dexamethasone pretreatment. However, it is unclear 
whether this also holds true for adrenocortical adenoma 
cells because ACTH (adrenocorticotropic hormone) receptor 
expression is low in NFAs.47 Nevertheless, the data obtained 
by the 11C-metomidate studies represent an important proof 
of principle demonstrating that the PET imaging technique 
per se may be of value in PA.44
Targeting CXCR4 in PA may be a promising alternative 
approach. This is highlighted by our 9 patients with APA who 
were investigated by 68Ga-pentixafor PET/CT. All patients 
showed focal 68Ga-pentixafor uptake in the adrenal nodule 
with SUV
max
 values ranging between 4.7 and 18.3 (mean, 
10.7), whereas the mean SUV
max
 value measured in non-PA 
patients was 3.3. Uptake values in APA significantly differed 
both from values obtained in controls and in the contralateral 
Figure 2. Chemokine receptor mRNA 
expression in adrenocortical adenomas. 
Relative chemokine receptor mRNA 
expression of CC chemokine receptors 
(left) and CXC chemokine receptors 
(right) in normal adrenal (NA, n=4), 
aldosterone-producing adenoma (APA, 
n=12), cortisol-producing adenoma (CPA, 
n=11), and nonfunctioning adenoma 
(NFA, n=3).
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adrenals. In 1 patient, APA measured only 6 mm and was not 
detected by 68Ga-pentixafor indicating the detection limit 
for small lesions because of reduced spatial resolution. In 2 
patients, 68Ga-pentixafor identified the tumor side, which was 
unable to be localized by AVS.
As a future approach, the combination of steroid pro-
filing by mass spectrometry as a first differential diag-
nostic step with subsequent functional imaging using 
68Ga-pentixafor PET/CT or 68Ga-pentixafor PET/mag-
netic resonance imaging could enable noninvasive diag-
nosis in most patients with PA. As furthermore 96% of 
NFA exhibited either low or no staining for CXCR4, no 
tracer uptake would be expected in these tumors. Because 
immunohistochemistry revealed low CXCR4 staining in 
29% of APAs, only this subgroup would remain for fur-
ther investigation by AVS. A small group of patients with 
NFA is expected to be false-positive in 68Ga-pentixafor 
PET imaging because 2 of these adenomas (4%) in our 
series showed high CXCR4 expression. On the contrary, 
we recently found high CXCR4 expression in adrenocorti-
cal carcinoma.48 Therefore, a high CXCR4 uptake in PET 
imaging generally might be associated with a lower thresh-
old for the decision for surgery. However, this would need 
to be corroborated by further studies. In both NFA patients 
with strong CXCR4 staining in our cohort, tumor growth 
was documented leading to the decision for adrenalectomy.
There are several limitations on the clinical aspects of our 
article: within this translational project, we did not perform 
a standardized clinical trial investigating healthy individu-
als, and the data used as controls were obtained from patient 
cohorts with malignant disease that had already undergone 
68Ga-pentixafor PET imaging for other clinical reasons. It 
is to date unclear whether concurrent chemotherapy might 
influence CXCR4 expression in vivo. Many malignant tumors 
exhibit high CXCR4 expression, and although no adrenal 
metastases were detected by conventional imaging, CXCR4-
positive micrometastases could not be excluded. Subgroup 
analysis of the 3 groups of control patients who received dif-
ferent treatments did, however, not reveal any group differ-
ences. Uptake values in the contralateral adrenals of patients 
with PA were not significantly higher compared with the con-
trols without PA.
Figure 3. The CXCR4 (CXC chemokine receptor type 4) ligand 68Ga-pentixafor specifically accumulates in aldosterone-producing 
tissue. Ex vivo experiments and clinical positron emission tomographic (PET) imaging. A, Ex vivo autoradiographic visualization of 68Ga-
pentixafor binding to cryosections of the normal adrenal gland (NA), aldosterone-producing adenoma (APA), adrenocortical carcinoma 
(ACC), and nonfunctioning adenoma (NFA). Red colors indicate highest binding of radio ligand, blue/dark blue colors indicate no binding 
or full competitive inhibition. A, 2MBq 68Ga-pentixafor; B, 2MBq 68Ga-pentixafor plus 10 µM of the nonradioactive ligand. Strong ligand 
binding that could be blocked by coincubation with the unlabeled tracer compound could be documented in NA, APA, and ACC. B and 
C, Representative images of 68Ga-pentixafor PET/computed tomographic (CT) imaging in 2 patients with APA: 68Ga-pentixafor imaging 
in a 47-year-old female patient with primary aldosteronism after injection of 152 MBq 68Ga-pentixafor (B). 68Ga-pentixafor-PET/CT of 
a 66-year-old male patient with primary aldosteronism after injection of 126 MBq 68Ga-pentixafor. C, White arrows indicate the tumor 
lesion. D, Maximum standardized uptake values (SUVmax) for 68Ga-pentixafor uptake in the adrenal of control subjects compared with 
patients with APA both at the tumor (APA tumor) and the contralateral (APA contralateral) side. Adrenal SUVmax values from controls are 
pooled data derived from both sides. E, Receiver operating characteristic analysis of SUVmax values. Data were obtained from controls 
(n=44; 86 values were obtained from measurement of the left and right adrenal; in 2 patients, only the left adrenal was available) and 9 
APAs. A cutoff value for SUVmax of 4.8 revealed a sensitivity of 89% (95% confidence interval [CI], 51.8–99.7) and a specificity of 85% 
(95% CI, 75.5–91.7). Setting specificity to 100% a cutoff value of 7.8 was calculated (sensitivity, 67%), whereas a sensitivity of 100% was 
reached at a cutoff value of 4.7 (specificity, 81%). Area under the curve, 0.964 (95% CI, 0.92–1.01).
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In our patient series, most tumor lesions were >1 cm. 
Many APAs are <1 cm, which generally limits the sensitivity 
of PET imaging because of the reduced spatial resolution of 
this imaging approach.49 Thus, 68Ga-pentixafor PET imaging 
may not fully replace but at least significantly reduce the num-
ber of AVS to a more selected patient subgroup.
Perspectives
Taken together, we have demonstrated that CXCR4 is highly 
abundant in the zona glomerulosa and in APAs suggesting 
a significant role in adrenocortical physiology and further 
representing a potential target for molecular imaging of 
aldosterone-producing tissue. Considering the need for uni-
versal diagnostic alternatives to AVS in PA, 68Ga-pentixafor 
PET represents a novel and promising tool for differential 
diagnosis that warrants further evaluation in a prospective 
clinical trial.
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What Is New?
•	CXCR4 (CXC chemokine receptor type 4) is highly expressed in the outer 
adrenocortical zones, as well as in aldosterone-producing adenomas, 
especially compared with nonfunctioning adenomas.
•	The CXCR4-specific positron emission tomographic tracer 68Ga-pen-
tixafor exhibits strong binding to cryosections of aldosterone-producing 
adenomas, adrenocortical carcinomas, and the outer adrenal cortex.
•	 First in vivo imaging studies show the potential suitability of CXCR4-
specific positron emission tomographic imaging for noninvasive subtype 
differentiation in patients with primary aldosteronism.
What Is Relevant?
•	Alternative tools for subtype differentiation in primary aldosteronism are 
urgently needed because of several drawbacks of the current diagnostic 
standard adrenal vein sampling. Given the high expression of CXCR4, 
especially in aldosterone-producing adenomas, as well as strong tracer 
binding of 68Ga-pentixafor to aldosterone-producing adenomas, CXCR4 
seems to be a suitable target for noninvasive characterization of adrenal 
lesions in primary aldosteronism.
Summary
CXCR4-targeted positron emission tomographic imaging repre-
sents a novel promising alternative to adrenal vein sampling for 
differential diagnosis in primary aldosteronism.
Novelty and Significance
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MATERIALS AND METHODS 
 
Immunohistochemical analysis 
 
As a screening test for primary aldosteronism the aldosterone / renin concentration ratio 
(ARR) after withdrawal of interfering drugs had been used and diagnosis of PA had 
subsequently been confirmed by saline infusion test. After confirmation of PA, 103 out of 
117 patients underwent adrenal vein sampling. In the remaining 14 patients the decision for 
adrenalectomy had been based on detection of an adrenal lesion in conventional adrenal 
imaging combined with younger age (below 45 years) and/or positive postural test. After 
adrenalectomy, surgical specimens underwent histopathological evaluation by a local 
pathologist. Unilateral disease was confirmed by normalization of ARR and potassium levels 
as well as cure or amelioration of hypertension at follow-up (available for 113/117 patients).  
All patients with cortisol producing adenoma had an abnormal dexamethasone suppression 
test defined as serum-cortisol level after 1 mg dexamethasone above 1.8 µg/dl. Mean serum 
cortisol levels after dexamethasone were 15.9 µg/dl (2.2 – 30.6 µg/dl). In addition, at least 
one further pathological test of the HPA axis was required for inclusion as CPA: 24 hour 
urine cortisol levels above the normal range and increased salivary or serum cortisol levels at 
midnight. 
Patients with non-functioning adrenocortical adenoma had no clinical evidence of hormone 
excess and furthermore normal tests results for aldosterone to renin ratio and cortisol levels.  
The respective local specialists of the departments of pathology confirmed histological 
diagnosis of adrenocortical adenoma. 
Tissue sections were deparaffinized in xylene for 2x12 min and dehydrated in ethanol (100%, 
90%, 80%, 70%, each concentration for 5 min). Immunohistochemical detection was 
performed using an indirect immunoperoxidase technique after high temperature antigen 
retrieval in 10 mM citric acid monohydrate buffer (pH 6.5) in a pressure cooker for 13 min. 
Blocking of unspecific protein-antibody interactions was performed with 20% human AB-
serum in PBS for 1 hour at room temperature. The primary CXCR4 antibody was used at a 
dilution of 1:100 at RT for 1 h together with the N-Universal Negative Control Anti-Rabbit 
(Dako, Glostrup, Denmark). CXCR4 and CXCL12 antibodies were from abcam (Cambridge, 
United Kingdom (12824, 9797)) Specific antibodies against human CYP11B1 (dilution 
1:100) and CYP11B2 (dilution 1:200) were kindly provided by Celso Gomez-Sanchez, 
University of Mississippi, USA. Signal amplification was achieved by En-Vision System 
Labeled Polymer-Horseradish peroxidase (Dako, Santa Clara, USA) for 40 min and 
developed for 10 min with Diaminobenzidine Substrate Kit (Vector Laboratories, 
Burlingame, CA, USA) according to the manufacturer’s instructions. Nuclei were 
counterstained with Mayer’s hematoxylin for 2 min. Negative controls were carried out by 
treating the slides with a nonimmune serum instead of the primary antibody, yielding a nearly 
complete loss of staining with only some faint background. 
The anti-CXCR4, anti-CYP11B2 and anti-CYP11B1 staining intensity was evaluated with a 
grading score of 0, 1, 2, or 3, which corresponded to negative, weak, moderate, or strong 
staining intensity, respectively. The percentage of positive tumor cells was calculated for 
each specimen and scored 0 if 0% were positive, 0.1 if 1–9%, 0.5 if 10–49%, and 1 if >50%. 
A semi-quantitative h-score was then calculated by multiplying the staining intensity grading 
score with the proportion score as previously described 1. Calculation of h-score was 
separately performed for membrane and cytoplasmatic staining in tumor tissue as well as the 
adjacent adrenal gland. For membrane and cytoplasmatic staining an h-score ≤ 1 was rated as 
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low, whereas and h-score > 1 was rated as high. Investigators were blinded to the patient 
data.  
 
Analysis of chemokine receptor expression in adrenocortical adenomas by quantitative PCR 
 
40 ng cDNA was used for each PCR reaction and each sample was performed in duplicate. 
Transcript levels were determined using the TaqMan Gene Expression Master Mix (Applied 
Biosystems, Foster City, USA), the CFX96 real-time thermocycler (Bio-Rad, Hercules, CA, 
USA) and Bio-Rad CFX Manager 2.0 software. Cycling conditions were 95°C for three min 
followed by 50 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec. Using the 
ΔCT method 2, the gene expression levels were normalized to those of b-actin.  
 
Autoradiographic experiments with 68Ga-Pentixafor  
Human tissues were snap-frozen in liquid nitrogen to block further biological processes 
including protein degradation and tissue hardening and stored at –80 °C. Experiments were 
repeated thrice. Before cutting, tissues were transferred to a –20 °C freezer. Frozen samples 
were sectioned in a micro-cryotome into 20 µm tissue slices for all tissues and thaw-mounted 
onto superfrost slides, dried and then stored at –80 °C until processing. A barrier pen was 
used (Invitrogen Mini PAP PEN, Zymed® Laboratories, Carlsbad, CA, USA). For the 
experimental set-up the tissue slices were fixated for 10 min with 0.4%PFA and then pre-
incubated for 5 min at room temperature with buffer solution (pH 7.4, 50 mM Tris). 
Afterwards the slices were incubated with 20% human AB-serum in PBS for 60 min. After 
blocking for 1 hour, one slide was treated with 2 MBq 68Ga-Pentixafor and another slide was 
incubated with 2 MBq 68Ga-Pentixafor plus 10 µM of the non-radioactive compound to 
monitor the specific binding. Slides were subsequently washed twice in 0.5% Tween 50 mM 
Tris HCl buffer solution (pH 7.4) and dried. Thereafter, samples were placed for 30 min on 
Phosphor Imager plates in dedicated lead shielded cassettes. Autoradiographic images were 
analyzed with a Phosphor Imager (CR35BIO Imageplate scanner) and data analysis was 
performed with Amide software Version 0.9.0 and Microsoft Excel® 2007.  
 
Imaging of patients by 68Ga-Pentixafor-PET 
In the four patients receiving PET/CT, corresponding CT low dose scans for attenuation 
correction were acquired using a low-dose protocol (20 mAs, 120keV, a 512x512 matrix, 
5mm slice thickness, increment of 30mm/s, rotation time of 0.5s, and pitch index of 0.8) 
including the base of the skull to the proximal thighs for the reference group and including 
one bed position over the abdomen for the patients with primary aldosteronism. 
Consecutively, PET emission data were acquired in three-dimensional mode with a 200x200 
matrix with 2-3min emission time per bed position. After decay and scatter correction, PET 
data were reconstructed iteratively with attenuation correction using a dedicated software 
(Siemens Esoft). 
In the remaining five patients, PET and MR data were simultaneously acquired for 20 min on 
the integrated PET/MR system 50 to 69 min after injection of 68Ga-Pentixafor. The PET 
scan was acquired in 3D-list-mode including PET-based respiratory gating, attenuation 
correction was accomplished using 2-point Dixon MR sequences. For anatomical correlation 
T1w and T2 fatsat axial sequences, as well as T2w coronal sequences were acquired.  
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In all cases 68Ga-Pentixafor scans were performed on a dedicated PET/CT (Siemens 
Biograph mCT 64 and Biograph mCT 128; Siemens Medical Solutions, Erlangen, Germany) 
or PET/MRI System (Siemens Biograph mMR; Siemens Medical Solutions, Erlangen, 
Germany). Injected activity ranged from 115 to 207 MBq and image acquisition started after 
50 to 86 min.  
Semi-quantitative PET scan analysis comprised calculation of the highest metabolic activity 
within each adrenal gland (maximum standardized uptake values, SUVmax) by 2D regions of 
interest (ROI) with a diameter of 1 cm around the hottest pixel. CT and MRI scans were read 
qualitatively by reporting the location and size of adrenal lesions.  
68Ga-Pentixafor was administered under the conditions of pharmaceutical law (The German 
Medicinal Products Act, AMG §13 2b) according to the German law and in accordance with 
the responsible regulatory body (Regierung von Unterfranken, Regierung von Oberbayern, 
Germany) 3. All patients gave written informed consent prior to 68Ga-Pentixafor-PET 
imaging. 
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Results 
 
 
Chemokine 
Receptor 
Taqman Gene 
Expression assay
CCR1 Hs00928897_s1
CCR2 Hs00704702_s1 
CCR3 Hs01847760_s1 
CCR4 Hs00747615_s1 
CCR5 Hs99999149_s1 
CCR6 Hs10890706_s1 
CCR7 Hs01013469_m1
CCR8 Hs00174764_m1
CCR9 Hs01890924_s1 
CCR10 Hs00706455_s1 
CCR11 Hs00664347_s1 
CXCR1 Hs01921207_s1 
CXCR2 Hs01891184_s1
CXCR3 Hs01847760_s1 
CXCR4 Hs00607978_s1 
CXCR5 Hs00540548_s1 
CXCR6 Hs01890898_s1 
CXCR7 Hs00664172_s1
b-actin Hs9999903_m1 
 
S1. Specific Taqman Gene Expression assays by Applied Biosystems (Darmstadt, Germany). 
 
 
 
S2. Immunohistochemical staining of CXCR4, CYP11B1 and CYP11B2 in aldosterone-
producing adenoma, Magnification 10x. 
 
